Literature DB >> 35896717

News and future perspectives of non-surgical treatments for erectile dysfunction.

Celeste Manfredi1, Fabio Castiglione2, Mikkel Fode3,4, Michal Lew-Starowicz5, Javier Romero-Otero6,7, Carlo Bettocchi8, Giovanni Corona9.   

Abstract

The significant discontinuation rate of available therapies and the paucity of curative options promoted the research on potential novel treatments suitable for erectile dysfunction patients. The aim of this study was to provide a summary of available evidence regarding the news and future perspectives related to the non-surgical treatment of erectile dysfunction. A narrative review of the literature was performed. A comprehensive search in the MEDLINE, Embase, and Scopus databases was done. Papers in English-language, published until April 2022, were included. No chronological restriction was applied. Retrospective and prospective clinical studies, as well as meta-analyses, were considered. Oro-dispersible formulations of phosphodiesterase type 5 inhibitors are particularly indicated in patients who have difficulty in swallowing solid dosage form; in addition, they constitute a discrete route of administration not requiring water. Low-intensity extracorporeal shock wave therapy is indicated in mild vasculogenic erectile dysfunction and in patients with vasculogenic erectile dysfunction poorly responsive to phosphodiesterase type 5 inhibitors. Stem cell therapy, platelet-rich plasma injections, and gene therapy seem promising regenerative treatments for selected patients with erectile dysfunction. Novel oral formulations of drugs commonly used in erectile dysfunction patients have recently become part of standard clinical practice. Regenerative treatments have been emerging in recent years and could become routine curative options in the near future. Further well-designed randomized controlled trials are needed to provide conclusive evidence on this topic and guide appropriate recommendations.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35896717     DOI: 10.1038/s41443-022-00602-3

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.408


  56 in total

Review 1.  Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil.

Authors:  I Moncada; J Martinez-Salamanca; E Ruiz-Castañe; J Romero
Journal:  Int J Impot Res       Date:  2018-07-26       Impact factor: 2.896

Review 2.  Penile Implant Surgery Satisfaction Assessment.

Authors:  Celeste Manfredi; Édouard Fortier; Antoine Faix; Juan Ignacio Martínez-Salamanca
Journal:  J Sex Med       Date:  2021-04-24       Impact factor: 3.802

3.  Topical prostaglandin-E1 for the treatment of erectile dysfunction.

Authors:  E D Kim; K T McVary
Journal:  J Urol       Date:  1995-06       Impact factor: 7.450

4.  Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.

Authors:  O I Linet; F G Ogrinc
Journal:  N Engl J Med       Date:  1996-04-04       Impact factor: 91.245

5.  Long-term results with vacuum constriction device.

Authors:  M S Cookson; P W Nadig
Journal:  J Urol       Date:  1993-02       Impact factor: 7.450

6.  Is topical alprostadil an usable and reliable alternative to intracavernous injection for penile dynamic duplex ultrasonography?

Authors:  Davide Arcaniolo; Giuseppe Bellastella; Celeste Manfredi; Marco Terribile; Dario Ranieri Giordano; Carmelo Quattrone; Roberto La Rocca; Marco De Sio; Paolo Verze; Vincenzo Mirone
Journal:  Andrologia       Date:  2019-11-11       Impact factor: 2.775

Review 7.  Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review.

Authors:  Paul Williams; Hayley McBain; Aliya Amirova; Stanton Newman; Kathleen Mulligan
Journal:  Int J Impot Res       Date:  2020-03-31       Impact factor: 2.896

8.  Comparison of Satisfaction With Penile Prosthesis Implantation in Patients With Radical Prostatectomy or Radical Cystoprostatectomy to the General Population.

Authors:  Skyler Howell; Stephen Palasi; Travis Green; Christopher Kannady; Sravan Panuganti; Kris Slaughter; Kyle Blum; Baibing Yang; Jose A Saavedra-Belaunde; Run Wang
Journal:  Sex Med       Date:  2021-01-08       Impact factor: 2.491

9.  Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study.

Authors:  Pablo Garrido-Abad; Isabel Senra-Bravo; Celeste Manfredi; Esaú Fernández-Pascual; Estefanía Linares-Espinós; Manuel Fernández-Arjona; David Varillas-Delgado; Juan Ignacio Martínez-Salamanca
Journal:  Int J Impot Res       Date:  2021-01-22       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.